Haemonetics Corp. (NYSE:HAE) was downgraded by investment analysts at CJS Securities from a “market outperform” rating to a “market perform” rating in a report issued on Tuesday.

A number of other analysts have also recently issued reports on the stock. Sidoti cut shares of Haemonetics Corp. from a “buy” rating to a “neutral” rating and set a $39.00 target price for the company. in a research note on Monday, August 15th. Zacks Investment Research cut shares of Haemonetics Corp. from a “hold” rating to a “sell” rating in a research note on Wednesday, August 3rd. Barrington Research cut shares of Haemonetics Corp. from an “outperform” rating to a “market perform” rating in a research note on Wednesday, August 3rd. Jefferies Group raised their target price on shares of Haemonetics Corp. from $32.00 to $40.00 and gave the stock a “buy” rating in a research note on Tuesday, August 2nd. Finally, Benchmark Co. raised their target price on shares of Haemonetics Corp. from $28.00 to $32.00 and gave the stock a “hold” rating in a research note on Tuesday, August 2nd. Two equities research analysts have rated the stock with a sell rating, eight have given a hold rating and one has given a buy rating to the company. Haemonetics Corp. currently has an average rating of “Hold” and an average target price of $34.40.

Analyst Recommendations for Haemonetics Corp. (NYSE:HAE)

Haemonetics Corp. (NYSE:HAE) opened at 37.16 on Tuesday. The firm’s market capitalization is $1.91 billion. The stock’s 50 day moving average is $36.39 and its 200-day moving average is $32.25. Haemonetics Corp. has a 12 month low of $25.98 and a 12 month high of $38.06.

Haemonetics Corp. (NYSE:HAE) last posted its earnings results on Monday, August 1st. The company reported $0.25 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.28 by $0.03. The company had revenue of $210 million for the quarter, compared to analyst estimates of $205.41 million. Haemonetics Corp. had a positive return on equity of 10.75% and a negative net margin of 7.25%. The business’s quarterly revenue was down 1.6% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.35 EPS. Equities analysts anticipate that Haemonetics Corp. will post $1.44 earnings per share for the current fiscal year.

In related news, CEO Christopher Simon purchased 60,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 4th. The shares were bought at an average cost of $35.00 per share, with a total value of $2,100,000.00. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Ronald Merriman sold 4,337 shares of Haemonetics Corp. stock in a transaction that occurred on Wednesday, August 17th. The shares were sold at an average price of $35.14, for a total transaction of $152,402.18. Following the sale, the director now directly owns 22,088 shares in the company, valued at $776,172.32. The disclosure for this sale can be found here. 1.50% of the stock is currently owned by company insiders.

Large investors have recently made changes to their positions in the stock. Louisiana State Employees Retirement System raised its stake in shares of Haemonetics Corp. by 0.4% in the second quarter. Louisiana State Employees Retirement System now owns 22,600 shares of the company’s stock valued at $655,000 after buying an additional 100 shares during the period. Profund Advisors LLC raised its stake in shares of Haemonetics Corp. by 0.9% in the second quarter. Profund Advisors LLC now owns 13,954 shares of the company’s stock valued at $405,000 after buying an additional 124 shares during the period. JPMorgan Chase & Co. raised its stake in shares of Haemonetics Corp. by 0.6% in the second quarter. JPMorgan Chase & Co. now owns 34,619 shares of the company’s stock valued at $1,003,000 after buying an additional 201 shares during the period. PineBridge Investments L.P. raised its stake in shares of Haemonetics Corp. by 4.2% in the second quarter. PineBridge Investments L.P. now owns 6,473 shares of the company’s stock valued at $187,000 after buying an additional 261 shares during the period. Finally, Fox Run Management L.L.C. raised its stake in shares of Haemonetics Corp. by 3.8% in the second quarter. Fox Run Management L.L.C. now owns 8,200 shares of the company’s stock valued at $238,000 after buying an additional 300 shares during the period. 98.64% of the stock is currently owned by institutional investors.

About Haemonetics Corp.

Haemonetics Corporation (Haemonetics) is a healthcare company. The Company provides various products to customers involved in the processing, handling and analysis of blood. The Company’s segments include Japan, EMEA, North America Plasma and All Other. Haemonetics provides plasma collection systems and software, which enable plasma fractionators to make pharmaceuticals.

5 Day Chart for NYSE:HAE

Receive News & Ratings for Haemonetics Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics Corp. and related companies with MarketBeat.com's FREE daily email newsletter.